RAD52 motif‑containing protein 1 promotes non‑small cell lung cancer cell proliferation and survival via cell cycle regulation

Xu,Guihua; Du,Jiya; Wang,Feng; Zhang,Fan; Hu,Ruimin; Sun,Dejun; Shen,Jie

doi:10.3892/or.2018.6459

RAD52 motif‑containing protein 1 promotes non‑small cell lung cancer cell proliferation and survival via cell cycle regulation

Authors:
- Guihua Xu
- Jiya Du
- Feng Wang
- Fan Zhang
- Ruimin Hu
- Dejun Sun
- Jie Shen
View Affiliations

Affiliations: Department of Clinical Medical Research Center, Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia 010017, P.R. China, Department of Pathology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia 010017, P.R. China, Department of Pathology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia 010017, P.R. China, Department of Respiratory and Critical Diseases, Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia 010017, P.R. China, Department of Respiratory and Critical Diseases, Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia 010017, P.R. China, Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia 010017, P.R. China
Published online on: May 23, 2018 https://doi.org/10.3892/or.2018.6459
Pages: 833-840

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA repair proteins such as RAD52 have been implicated in tumor progression and response to chemotherapy. RAD52 motif‑containing protein 1 (RDM1) has been implicated in the response to chemotherapeutic agent cisplatin; however, its function in lung cancer progression remains unclear. This study aimed to investigate the role of RDM1 in the progression of non‑small cell lung cancer (NSCLC). We found elevated RDM1 mRNA and protein expression in NSCLC tissues and cell lines compared to levels in normal lung cells. RDM1 protein expression in lung cancer tissues was found to correlate with tumor size, histological differentiation, lymph node metastasis and tumor‑node‑metastasis (TNM) stage. Knockdown of the RDM1 gene with siRNA significantly reduced the cellular proliferation rate and increased apoptosis in the human NSCLC cell line, NCI‑H1299. Compared to wild‑type NCI‑H1299 cells, RDM1 knockdown enhanced the activity of caspase‑3 and caspase‑7, and decreased the proportion of cells in the S‑phase of the cell cycle. Taken together, these data imply that RDM1 promotes the survival and proliferation of NSCLC cells. Due to its similarity to RAD52, we hypothesized that RDM1 potentially repairs DNA double‑strand breaks arising through DNA replication, thereby preventing G2/M cell cycle arrest. Accordingly, specific targeting of RDM1 may be a novel therapeutic strategy in the treatment of NSCLC.

View Figures

View References

1	Ridge CA, McErlean AM and Ginsberg MS: Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98. 2013. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
3	Calikusu Z, Yildirim Y, Akcali Z, Sakalli H, Bal N, Unal I and Ozyilkan O: The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. J Exp Clin Cancer Res. 28:972009. View Article : Google Scholar : PubMed/NCBI
4	Chan BA and Hughes BG: Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res. 4:36–54. 2015.PubMed/NCBI
5	Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R and Salgia R: Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 5:1392–1433. 2014. View Article : Google Scholar : PubMed/NCBI
6	Maione P, Sacco PC, Sgambato A, Casaluce F, Rossi A and Gridelli C: Overcoming resistance to targeted therapies in NSCLC: Current approaches and clinical application. Ther Adv Med Oncol. 7:263–273. 2015. View Article : Google Scholar : PubMed/NCBI
7	Salehan MR and Morse HR: DNA damage repair and tolerance: A role in chemotherapeutic drug resistance. Br J Biomed Sci. 70:31–40. 2013. View Article : Google Scholar : PubMed/NCBI
8	Lieberman R and You M: Corrupting the DNA damage response: A critical role for Rad52 in tumor cell survival. Aging. 9:1647–1659. 2017.PubMed/NCBI
9	Lieberman R, Pan J, Zhang Q and You M: Rad52 deficiency decreases development of lung squamous cell carcinomas by enhancing immuno-surveillance. Oncotarget. 8:34032–34044. 2017. View Article : Google Scholar : PubMed/NCBI
10	Rajaee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Dienemann H, Schulz V, Drings P, Thiel S and Bartsch H: Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int J Cancer. 95:86–91. 2001. View Article : Google Scholar : PubMed/NCBI
11	Spitz MR, Wei Q, Dong Q, Amos CI and Wu X: Genetic susceptibility to lung cancer: The role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev. 12:689–698. 2003.PubMed/NCBI
12	Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S and Stuerzbecher HW: High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer. 93:137–143. 2005. View Article : Google Scholar : PubMed/NCBI
13	Benson FE, Baumann P and West SC: Synergistic actions of Rad51 and Rad52 in recombination and DNA repair. Nature. 391:401–404. 1998. View Article : Google Scholar : PubMed/NCBI
14	Hamimes S, Arakawa H, Stasiak AZ, Kierzek AM, Hirano S, Yang YG, Takata M, Stasiak A, Buerstedde JM and Van Dyck E: RDM1, a novel RNA recognition motif (RRM)-containing protein involved in the cell response to cisplatin in vertebrates. J Biol Chem. 280:9225–9235. 2005. View Article : Google Scholar : PubMed/NCBI
15	Hamimes S, Bourgeon D, Stasiak AZ, Stasiak A and Van Dyck E: Nucleic acid-binding properties of the RRM-containing protein RDM1. Biochem Biophys Res Commun. 344:87–94. 2006. View Article : Google Scholar : PubMed/NCBI
16	Messaoudi L, Yang YG, Kinomura A, Stavreva DA, Yan G, Bortolin-Cavaillé ML, Arakawa H, Buerstedde JM, Hainaut P, Cavaillé J, et al: Subcellular distribution of human RDM1 protein isoforms and their nucleolar accumulation in response to heat shock and proteotoxic stress. Nucleic Acids Res. 35:6571–6587. 2007. View Article : Google Scholar : PubMed/NCBI
17	Stubbs M, McSheehy PM, Griffiths JR and Bashford CL: Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 6:15–19. 2000. View Article : Google Scholar : PubMed/NCBI
18	Zhang F, Chen X, Wei K, Liu D, Xu X, Zhang X and Shi H: Identification of key transcription factors associated with lung squamous cell carcinoma. Med Sci Monit. 23:172–206. 2017. View Article : Google Scholar : PubMed/NCBI
19	Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, et al: The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
20	Li HM, Yuan P, Yu D, Ma F, Tan WW, Feng T, Yang J, Huang Y, Lin DX, Xu BH and Tan W: Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients. Zhonghua Zhong Liu Za Zhi. 38:504–509. 2016.(In Chinese). PubMed/NCBI
21	Ghosh S and Krishna M: Role of Rad52 in fractionated irradiation induced signaling in A549 lung adenocarcinoma cells. Mutat Res. 729:61–72. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kelley MR, Logsdon D and Fishel ML: Targeting DNA repair pathways for cancer treatment: What's new? Future Oncol. 10:1215–1237. 2014. View Article : Google Scholar : PubMed/NCBI
23	Han S, Gao F, Yang W, Ren Y, Liang X, Xiong X, Pan W, Zhou L, Zhou C, Ma F and Yang M: Identification of an SCLC susceptibility rs7963551 genetic polymorphism in a previously GWAS-identified 12p13.33 RAD52 lung cancer risk locus in the Chinese population. Int J Clin Exp Med. 8:16528–16535. 2015.PubMed/NCBI
24	Branzei D and Foiani M: Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol. 9:297–308. 2008. View Article : Google Scholar : PubMed/NCBI
25	Lok BH and Powell SN: Molecular pathways: Understanding the role of Rad52 in homologous recombination for therapeutic advancement. Clin Cancer Res. 18:6400–6406. 2012. View Article : Google Scholar : PubMed/NCBI
26	Bhowmick R, Minocherhomji S and Hickson ID: RAD52 facilitates mitotic DNA synthesis following replication stress. Mol Cell. 64:1117–1126. 2016. View Article : Google Scholar : PubMed/NCBI
27	Sotiriou SK, Kamileri I, Lugli N, Evangelou K, Da-Ré C, Huber F, Padayachy L, Tardy S, Nicati NL, Barriot S, et al: Mammalian RAD52 functions in break-induced replication repair of collapsed DNA replication forks. Mol Cell. 64:1127–1134. 2016. View Article : Google Scholar : PubMed/NCBI
28	Barlow JH and Rothstein R: Timing is everything: Cell cycle control of Rad52. Cell Div. 5:72010. View Article : Google Scholar : PubMed/NCBI
29	Sonoda E, Sasaki MS, Buerstedde JM, Bezzubova O, Shinohara A, Ogawa H, Takata M, Yamaguchi-Iwai Y and Takeda S: Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J. 17:598–608. 1998. View Article : Google Scholar : PubMed/NCBI
30	Henning W and Sturzbecher HW: Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology. 193:91–109. 2003. View Article : Google Scholar : PubMed/NCBI